Anna M. Esteve-rekin lankidetzan egindako argitalpenak (7)

2016

  1. Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients with HIV Infection or HIV/Hepatitis C Virus Coinfection

    Clinical Infectious Diseases, Vol. 62, Núm. 12, pp. 1578-1585

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: The experience of the PISCIS Cohort

    Clinical Microbiology and Infection, Vol. 19, Núm. 7, pp. 646-653

2009

  1. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

2008

  1. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS cohort (Spain)

    Journal of Acquired Immune Deficiency Syndromes, Vol. 47, Núm. 2, pp. 212-220

  2. HIV-1 infected patients older than 50 years. PISCIS cohort study

    Journal of Infection, Vol. 57, Núm. 1, pp. 64-71

2005

  1. Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS

    Medicina Clinica, Vol. 124, Núm. 14, pp. 525-531